PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...

PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th.The biopharmaceutical company reported ($1.39) EPS for the quarter, beating ...

S&P 500, Nasdaq post record highs as tech-related shares gain December 2, 2024 Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a ...

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up ...

Welcoming Gabrielle to the role, Simon McKeever, Chief Executive of the IEA, said: “We are delighted that Gabrielle will ...